Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
Provided by
Dow Jones
By Denny Jacob
Biogen's Skyclarys was authorized by the European Commission to treat neurodegenerative disease Friedreich's ataxia in adults and adolescents ages 16 and up.
The biopharmaceutical company said the regulatory body approved Skyclarys based on efficacy and safety data from a placebo-controlled trial.
Early symptoms of Friedreich's ataxia typically appear in childhood and include progressive loss of coordination, muscle weakness and fatigue.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 12, 2024 16:46 ET (21:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?